Batavia Bioservices and UvA Holding Announce STEP™ Technology Exclusive License
News Apr 29, 2013
Under the agreement, Batavia Bioservices has been granted the exclusive license to the STEP™ technology, a revolutionary, plasmid-based system that significantly reduces the time required to develop recombinant protein-producing mammalian cell lines while increasing protein production more than 10-fold.
Menzo Havenga (CEO Batavia Bioservices) commented: “We are very pleased that UvA Holding has selected Batavia Bioservices as its marketing partner for STEP™ technology since we firmly believe that this technology will significantly reduce manufacturing costs."
Chris Yallop (COO Batavia Bioservices) added: “STEP™ technology also allows the development of so-called rare diseases biopharmaceutical products, which have always been considered too expensive to develop."
Piet Scholten (Director UvA Holding BV) concluded: “With their in-depth know how in biopharm manufacturing, vast network, and presence in both Europe and USA, Batavia Bioservices provided the ideal landing platform for marketing our technology and we look forward to a fruitful relationship!”
Financial details of the exclusive license agreement were not disclosed.
Cow Antibodies Yield Important Clues For Developing A Broadly Effective AIDS VaccineNews
The unexpected animal model is providing clues for important questions at a moment when new energy has infused HIV vaccine research.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018
EMBL Course: Introduction to Metabolomics Analysis
Mar 20 - Mar 23, 2018